Imepitoin (Pexion) for Canine Idiopathic Epilepsy: Evidence Review

Bottom line

• Imepitoin (Pexion) is a low-affinity partial agonist of the benzodiazepine receptor approved in Europe for reducing seizure frequency in dogs with idiopathic epilepsy. [1]
• In a randomised controlled field trial (n=127), 37.5% of dogs on the high-dose regimen became seizure-free during the 12-week blinded phase; the antiepileptic effect was maintained through 6 months. [2]
• A pivotal non-inferiority field trial (n=226) found mean seizure frequency reduced to 1.1 per month in both the imepitoin group and the phenobarbital comparator group; 47% of imepitoin-treated evaluable dogs were seizure-free at 12 weeks. [1]
• Imepitoin showed fewer adverse events for polyuria, polydipsia, and marked sedation compared to phenobarbital; no hepatic enzyme increases were observed. [1]
• Not recommended as primary treatment when cluster seizures or status epilepticus are present; these forms were not investigated in pivotal trials. [1]

Drug facts

• Class: Novel antiepileptic, imidazolinone derivative
• Mechanism: Low-affinity partial agonist at the benzodiazepine receptor; potentiates GABA_A receptor-mediated neuronal inhibition; weak calcium channel blocking effect may contribute
• Route/interval: Oral; twice daily approximately 12 hours apart
• Indication: Reduction of frequency of generalised seizures due to idiopathic epilepsy in dogs; also approved for noise phobia-related anxiety in dogs
• Approval: EMA first authorisation 25 February 2013; EU/2/12/147 (Boehringer Ingelheim Vetmedica GmbH) [1]
• Label contraindications: Hypersensitivity to imepitoin; severe hepatic impairment; severe renal or cardiovascular disorders [1]
• Label common AEs: Polyphagia (very common, especially at initiation); hyperactivity, polyuria, polydipsia, somnolence, hypersalivation, emesis, ataxia, apathy, diarrhoea; mild and generally transient [1]

A specific patient on imepitoin?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=imepitoin-canine-idiopathic-epilepsy

What the evidence shows

Pivotal dose-finding RCT (Rundfeldt, Tipold, and Loscher 2015)

Rundfeldt et al. conducted a multicentre double-blind randomised controlled field trial at nine European veterinary neurology referral centres enrolling 127 dogs with newly diagnosed idiopathic epilepsy. Dogs were randomised 1:1 to high-dose or low-dose imepitoin for 12 weeks, followed by a 12-week open-label continuation on the high dose.

Monthly seizure frequency dropped significantly in the high-dose group; the mean reduction was 1.7 (+/- 2.8) seizures per month versus 0.8 (+/- 2.0) per month for the low-dose group (p=0.044). During the blinded phase, 37.5% of high-dose dogs and 31.7% of low-dose dogs became seizure-free; the difference was not significant, reflecting higher baseline seizure burden in the high-dose group by randomisation. When low-dose dogs were stepped up to the high dose in the open-label phase, the seizure-free rate rose to 46.8% (22 of 47 dogs).

Crucially, antiepileptic activity did not wane over 6 months of continuous high-dose treatment, indicating no tolerance development in a clinical setting. [2]

European non-inferiority comparison with phenobarbital (Pexion SPC, 2013)

The pivotal European field trial that supported EU marketing authorisation compared imepitoin with phenobarbital in 226 dogs with newly diagnosed idiopathic epilepsy. After excluding non-responders (45% of the imepitoin group and 20% of the phenobarbital group), mean generalised seizure frequency fell from 2.3 per month at baseline to 1.1 per month after 20 weeks in the imepitoin group, mirroring the same reduction in the phenobarbital group. The difference in seizure frequency between groups was 0.004 (95% CI -0.928, 0.935), meeting the pre-specified non-inferiority margin.

During the 12-week evaluation phase, 47% of imepitoin-treated evaluable dogs and 58% of phenobarbital-treated evaluable dogs were free of generalised seizures.

Safety data from the full safety population (116 imepitoin, 110 phenobarbital) showed that increasing phenobarbital doses were associated with rising liver enzymes (ALT, AP, AST, GGT, GLDH); none of the five enzymes increased with increasing imepitoin doses. Fewer adverse events were reported for polyuria (10% vs 19%), polydipsia (14% vs 23%), and marked sedation (14% vs 25%) in the imepitoin compared to the phenobarbital group. [1]

Mechanism and pharmacokinetics

Imepitoin is classified as an imidazolinone and acts as a low-affinity partial agonist at the benzodiazepine receptor, potentiating GABA_A-mediated inhibition. Because it is a partial, not full, agonist, the theoretical ceiling effect limits both maximal efficacy and the degree of sedation compared to classic benzodiazepines. The product shows no tolerance development in experimental models lasting up to 4 weeks. [1]

Imepitoin is well absorbed after oral administration (bioavailability >92%), achieving peak blood concentrations in approximately 2 hours; food reduces AUC by 30% without affecting Tmax or Cmax. Elimination half-life is approximately 1.5-2 hours. The drug is predominantly excreted via faeces, so pharmacokinetic accumulation is not expected in renally impaired dogs. [1]

Safety and adverse reactions

CNS-related adverse reactions in the Rundfeldt 2015 study were predominantly ataxia, disorientation, hyperactivity, and restlessness; importantly, these were transient, occurring mainly in the first weeks of treatment, and resolved with continued dosing. No hepatic enzyme increases and no other organ toxicity were observed. A marginal creatinine increase was noted but remained within normal range. [2]

The label lists polyphagia as a very common adverse reaction at treatment initiation. Mild elevation of plasma creatinine and cholesterol may be seen but levels remain within normal reference ranges. Aggression has been uncommonly reported in post-marketing experience and may be treatment-related or peri-ictal. [1]

How this fits clinical practice

Imepitoin is positioned as an alternative first-line option for dogs with newly diagnosed generalised idiopathic epilepsy, particularly in cases where the safety profile of phenobarbital (hepatotoxicity risk, polyuria/polydipsia/polyphagia, sedation) is a concern, or where the logistics of phenobarbital monitoring are a barrier. The product's limitations include a higher rate of initial non-response than phenobarbital, and the explicit exclusion from use as primary treatment for dogs with cluster seizures or status epilepticus, which were not investigated in pivotal trials. Efficacy as add-on therapy has not been demonstrated, and the label advises gradual transition if switching from another antiepileptic.

For daily clinical use, awareness of the expected polyphagia at onset and transient CNS signs during the first weeks of therapy helps set owner expectations. Confirmation that no blood monitoring of liver enzymes is required differs from phenobarbital management and may improve owner compliance.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=imepitoin-canine-idiopathic-epilepsy

References

1. Boehringer Ingelheim Vetmedica GmbH. Pexion 100 mg / 400 mg tablets for dogs — Summary of Product Characteristics (Annex I). European Commission community register; 2016. https://ec.europa.eu/health/documents/community-register/2016/20160418134614/anx_134614_en.pdf
2. Rundfeldt C, Tipold A, Loscher W. Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up. BMC Vet Res. 2015;11:228. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556053/

Changelog

• 2026-06-07: First published.